On Tuesday, Johnson & Johnson (NYSE:JNJ) reported first-quarter adjusted EPS of $2.71, up 12.4% year-on-year, beating estimates of $2.64. The drug giant reported sales of $21.38 billion, a year-over-year increase of 2.31 TP3T, almost in line with the consensus of $21.39 billion. Operating growth was 3.91 TP3T, compared to adjusted operating growth of 4.01 TP3T. JNJ reported a net profit of $5.35 billion, compared to a net loss of ($491) million in the same period last year, which included a $6.9 billion litigation charge. Innovation

Stocks are expected to rebound broadly from the sharp sell-off as investors digest the industry merit of U.S. banks and other heavyweights.

(Bloomberg) -- China's beef imports are falling amid slowing consumption and ample domestic supplies, hitting its biggest supplier, Brazil. Bloomberg's Most Popular Reads Beyond the Ivy League: Surprise Winners on the List of Colleges with the Highest ROI China Tells Iran Both Sides of Fight Will Continue After Israel Attack U.S. Two-Year Yield Closes in on 51 Ahead of Powell's Speech TP3T: Iran-Israel Rush Puts U.S. Ally Jordan in Jeopardy Officia

Some investors may be frustrated at missing out on Nvidia's significant gains.